Cipla gains on unveiling generic hepatitis C drug 'Hepcvir-L'

22 Dec 2015 Evaluate

Cipla is currently trading at Rs. 647.15, up by 4.05 points or 0.63% from its previous closing of Rs. 643.10 on the BSE.

The scrip opened at Rs. 643.10 and has touched a high and low of Rs. 648.15 and Rs. 643.10 respectively. So far 1,195 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 572.00 on 15-Jun-2015.

Last one week high and low of the scrip stood at Rs. 649.00 and Rs. 636.95 respectively. The current market cap of the company is Rs. 51,989.00 crore.

The promoters holding in the company stood at 36.79% while Institutions and Non-Institutions held 34.24% and 26.63% respectively.

Cipla has unveiled generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India. Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patient. The company's product is a generic version of the S-based drug maker Gilead Sciences Inc's Harvoni tablets.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.




Cipla Share Price

1486.30 20.65 (1.41%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.